Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer

Friday, May 17, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Liquid biopsy-based Precision Medicine test to guide patient selection for Inovio's VGX-3100

QIAGEN

Investors

Media

John Gilardi

Dr. Thomas Theuringer

+49 2103 29 11711

+49 2103 29 11826

ir@QIAGEN.com 

pr@QIAGEN.com

Inovio Pharmaceuticals Inc.

Investors

Media

Ben Matone

Jeffrey C. Richardson

1-484-362-0076

1-267-440-4211

ben.matone@inovio.com 

jrichardson@inovio.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store